Oncotype DX Colon Recurrence Score®
Colon cancer is the third most prevalent cancer for both men and women in the United States. It’s also the second most common cause of cancer-related deaths
The Oncotype DX Colon Recurrence Score test is clinically validated to quantify the risk of recurrence of patients with anatomic stage II, MMR-P and stage III A/B colon cancers. The 12-gene genomic test (seven cancer-related genes and five reference genes) looks at the underlying biology of a patient’s tumor so patients can choose a treatment that fits their unique situation.

References
- American Cancer Society Colon Cancer Facts & Figure 2020-2022: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf